KG Thusu, FC Morin 3rd, JA Russell and RH Steinhorn
Department of Pediatrics, State University of New York at Buffalo, USA.

We investigated the effect of zaprinast (M&B 22948), a specific cGMP phosphodiesterase inhibitor, on pulmonary arteries isolated from lambs with persistent pulmonary hypertension following prenatal ligation of the ductus arteriosus. Relaxations to sodium nitroprusside, which donates nitric oxide inside the smooth muscle cell, were significantly decreased in pulmonary arteries from ligated lambs. Pretreatment with 3 x 10(-5) M zaprinast restored them to levels close to those observed in untreated arteries from control animals. Further studies in intact newborn lambs were then conducted under three experimental conditions: (1) NO inhalation at 6 ppm, (2) zaprinast infusion at 0.05 mg/kg/min, and (3) combination therapy of zaprinast infusion in addition to inhaled NO at 6 ppm. Combined therapy with NO and zaprinast decreased the pulmonary artery pressure (34.3 +/- 3%) and pulmonary vascular resistance (64 +/- 7%) and increased pulmonary blood flow (88 +/- 34%) and postductal PaO2 (287 +/- 34%) to a significantly greater extent than NO alone, zaprinast alone, or the sum of these two responses, indicating a true synergistic effect. Zaprinast pretreatment also markedly increased the duration of pulmonary vasodilation to nitric oxide. There was no effect on systemic blood pressure with the combined therapy. We conclude that zaprinast pretreatment significantly enhances the effect of sodium nitroprusside on isolated pulmonary arteries, as well the effect of inhaled NO at 6 ppm in newborn lambs with persistent pulmonary hypertension. We speculate that phosphodiesterase inhibition may increase the response rate to NO or allow the use of much lower inhaled concentrations of NO.

This article has been cited by other articles:

				M. Chester, P. Tourneux, G. Seedorf, T. R. Grover, J. Gien, and S. H. Abman Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus Am J Physiol Lung Cell Mol Physiol, August 1, 2009; 297(2): L318 - L325. [Abstract] [Full Text] [PDF]

				K. D. Bloch, F. Ichinose, J. D. Roberts Jr., and W. M. Zapol Inhaled NO as a therapeutic agent Cardiovasc Res, July 15, 2007; 75(2): 339 - 348. [Abstract] [Full Text] [PDF]

				K. Subramaniam and J.-P. Yared Management of Pulmonary Hypertension in the Operating Room Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 119 - 136. [Abstract] [PDF]

				S. Jaillard, B. Larrue, P. Deruelle, A. Delelis, T. Rakza, G. Butrous, and L. Storme Effects of Phosphodiesterase 5 Inhibitor on Pulmonary Vascular Reactivity in the Fetal Lamb Ann. Thorac. Surg., March 1, 2006; 81(3): 935 - 942. [Abstract] [Full Text] [PDF]

				R. C. Dukarm, R. H. Steinhorn, J. A. Russell, S. Lakshminrusimha, D. Swartz, and J. J. Cummings Selective type 5 phosphodiesterase inhibition alters pulmonary hemodynamics and lung liquid production in near-term fetal lambs J Appl Physiol, December 1, 2005; 99(6): 2331 - 2336. [Abstract] [Full Text] [PDF]

				B. Larrue, S. Jaillard, M. Lorthioir, X. Roubliova, G. Butrous, T. Rakza, H. Warembourg, and L. Storme Pulmonary vascular effects of sildenafil on the development of chronic pulmonary hypertension in the ovine fetus Am J Physiol Lung Cell Mol Physiol, June 1, 2005; 288(6): L1193 - L1200. [Abstract] [Full Text] [PDF]

				A. L. Trachte, E. B. Lobato, F. Urdaneta, P. J. Hess, C. T. Klodell, T. D. Martin, E. D. Staples, and T. M. Beaver Oral Sildenafil Reduces Pulmonary Hypertension After Cardiac Surgery Ann. Thorac. Surg., January 1, 2005; 79(1): 194 - 197. [Abstract] [Full Text] [PDF]

				F. Urdaneta, J. L. Willert, T. Beaver, B. Naik, D. S. Kirby, and E. B. Lobato Effects of a New Phosphodiesterase Enzyme Type V Inhibitor (UK 343-664) Versus Milrinone in a Porcine Model of Acute Pulmonary Hypertension Ann. Thorac. Surg., October 1, 2004; 78(4): 1433 - 1437. [Abstract] [Full Text] [PDF]

				D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]

				I. Matot and Y. Gozal Pulmonary Responses to Selective Phosphodiesterase-5 and Phosphodiesterase-3 Inhibitors Chest, February 1, 2004; 125(2): 644 - 651. [Abstract] [Full Text] [PDF]

				M. R. Bonnell, F. Urdaneta, D. S. Kirby, N. R. Valdez, T. M. Beaver, and E. B. Lobato Effects of sildenafil analogue UK 343-664 on a porcine model of acute pulmonary hypertension Ann. Thorac. Surg., January 1, 2004; 77(1): 238 - 242. [Abstract] [Full Text] [PDF]

				L. Foubert, D. De Wolf, K. Reyntjens, Y. Van Belleghem, F. De Somer, G. Van Nooten, and E. Mortier Intermittent Nitric Oxide Combined with Intravenous Dipyridamole in a Piglet Model of Acute Pulmonary Hypertension Anesth. Analg., November 1, 2003; 97(5): 1497 - 1500. [Abstract] [Full Text] [PDF]

				L. S. Shekerdemian, H. B. Ravn, and D. J. Penny Intravenous Sildenafil Lowers Pulmonary Vascular Resistance in a Model of Neonatal Pulmonary Hypertension Am. J. Respir. Crit. Care Med., April 15, 2002; 165(8): 1098 - 1102. [Abstract] [Full Text] [PDF]

				R. H. STEINHORN, G. ALBERT, D. D. SWARTZ, J. A. RUSSELL, C. R. LEVINE, and J. M. DAVIS Recombinant Human Superoxide Dismutase Enhances the Effect of Inhaled Nitric Oxide in Persistent Pulmonary Hypertension Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 834 - 839. [Abstract] [Full Text] [PDF]

				R. T. Schermuly, N. Weissmann, B. Enke, H. A. Ghofrani, W. G. Forssmann, F. Grimminger, W. Seeger, and D. Walmrath Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension . Synergism upon Coapplication Am. J. Respir. Cell Mol. Biol., August 1, 2001; 25(2): 219 - 225. [Abstract] [Full Text] [PDF]

				R. F. Lodato Viagra for Impotence of Pulmonary Vasodilator Therapy? Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 312 - 313. [Full Text]

				H. Schutte, M. Witzenrath, K. Mayer, N. Weissmann, A. Schell, S. Rosseau, W. Seeger, and F. Grimminger The PDE inhibitor zaprinast enhances NO-mediated protection against vascular leakage in reperfused lungs Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L496 - L502. [Abstract] [Full Text] [PDF]

				R. C. DUKARM, J. A. RUSSELL, F. C. MORIN III, B. J. PERRY, and R. H. STEINHORN The cGMP-specific Phosphodiesterase Inhibitor E4021 Dilates the Pulmonary Circulation Am. J. Respir. Crit. Care Med., September 1, 1999; 160(3): 858 - 865. [Abstract] [Full Text]

				H. Hayakawa, Y. Hirata, M. Kakoki, Y. Suzuki, H. Nishimatsu, D. Nagata, E. Suzuki, K. Kikuchi, T. Nagano, K. Kangawa, et al. Role of Nitric Oxide–cGMP Pathway in Adrenomedullin-Induced Vasodilation in the Rat Hypertension, February 1, 1999; 33(2): 689 - 693. [Abstract] [Full Text] [PDF]

				J. W. ZIEGLER, D. D. IVY, J. W. WIGGINS, J. P. KINSELLA, W. R. CLARKE, and S. H. ABMAN Effects of Dipyridamole and Inhaled Nitric Oxide in Pediatric Patients with Pulmonary Hypertension Am. J. Respir. Crit. Care Med., November 1, 1998; 158(5): 1388 - 1395. [Abstract] [Full Text] [PDF]

				D. D. Ivy, J. P. Kinsella, J. W. Ziegler, and S. H. Abman Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease J. Thorac. Cardiovasc. Surg., April 1, 1998; 115(4): 875 - 882. [Abstract] [Full Text] [PDF]

				J. W. ZIEGLER, D. DUNBAR IVY, J. J. FOX, J. P. KINSELLA, W. R. CLARKE, and S. H. ABMAN Dipyridamole Potentiates Pulmonary Vasodilation Induced by Acetylcholine and Nitric Oxide in the Ovine Fetus Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1104 - 1110. [Abstract] [Full Text] [PDF]

				H. Hebestreit, B. Dibbert, I. Balatti, D. Braun, A. Schapowal, K. Blaser, and H.-U. Simon Disruption of Fas Receptor Signaling by Nitric Oxide in Eosinophils J. Exp. Med., February 2, 1998; 187(3): 415 - 425. [Abstract] [Full Text] [PDF]

				M. R. Maclean, E. D. Johnston, K. M. Mcculloch, L. Pooley, M. D. Houslay, and G. Sweeney Phosphodiesterase Isoforms in the Pulmonary Arterial Circulation of the Rat: Changes in Pulmonary Hypertension J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 619 - 624. [Abstract] [Full Text]

				N. FINER Inhaled nitric oxide in neonates Arch. Dis. Child. Fetal Neonatal Ed., September 1, 1997; 77(2): 81F - 84. [Full Text]